Daytrading mit Glückstreffer für 100 Euro.
Seite 2 von 11 Neuester Beitrag: 24.04.21 23:13 | ||||
Eröffnet am: | 19.05.15 20:43 | von: Glückstreffe. | Anzahl Beiträge: | 263 |
Neuester Beitrag: | 24.04.21 23:13 | von: Karinjvjha | Leser gesamt: | 27.104 |
Forum: | Hot-Stocks | Leser heute: | 6 | |
Bewertet mit: | ||||
Seite: < 1 | | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 11 > |
MFG
Chali
Euro brutto, hab mal meinen Tagessatz vor Pfingsten erhöht.
Will ja gut Essen und Trinken über Pfingsten.
Das Auto ist gepackt, geht gleich auf die Bahn.
Du packst nur Mist an, schlimm, schlimm.
Dex Media kostet keinen Dollar mehr, schon bei 2 Dollar hatte ich Dich gewarnt. Deinen Empfehlungsthread zu DXM haste besser gelöscht, gell?
ACI und ANR jeweils 0,65 Cent.
Und jetzt JoYou, Posting 27 von Dir.
Völlig überschuldet
Joyou ist pleite
Stand: 22.05.2015, 09:00 Uhr
Schon wieder entsteht mit einer in Frankfurt notierten China-Aktie ein Totalverlust. Die chinesische Grohe-Tochter Joyou hat einen Insolvenzantrag gestellt.
Als Grund wurde eine Abschreibung auf die Beteiligung an einem Hongkonger Unternehmen genannt. Der Aufsichtsrat habe zudem Jianshe Cai und Jilin Cai mit sofortiger Wirkung als Mitglieder des Vorstands der Gesellschaft abberufen.
Außerdem wurden "umfassende rechtliche Schritte" gegen die beiden Ex-Vorstände eingeleitet, wie es hieß. Bereits am Mittwoch hatte Joyou mitgeteilt, der Vorstand prüfe einen Insolvenzantrag. Das Unternehmen habe durch eine außerplanmäßige Abschreibung auf die Beteiligung an einem Hongkonger Unternehmen mehr als die Hälfte des Grundkapitals verloren.
Aktie wird zum Pennystock
Joyou
Joyou: Kursverlauf am Börsenplatz Xetra für den Zeitraum Intraday
Kurs
0.37
Differenz absolut
-0.18
Differenz relativ
-32.84%
Die Anleger reagieren bestürzt. Die Joyou-Aktie war am Donnerstag um 85 Prozent eingebrochen auf nur noch 54 Cent. Am Morgen geht der Kurssturz weiter auf nur noch 24 Cent. Damit ist das Papier binnen kurzer Zeit zum Pennystock geworden. Vor gut einem Monat notierte der Titel noch bei 16 Euro.
Leidtragender des Kursverfalls ist vor allem Grohe. Der von der japanischen Lixil-Gruppe übernommene Bad-Armaturenhersteller hält 72 Prozent Anteile an Joyou.
Bilanzen offenbar geschönt
Ende April hatte Grohe mitgeteilt, wegen Ungereimtheiten in den Bilanzen die Bücher von Joyou zu durchleuchten. Erste Untersuchungen ergaben, dass die Vermögens-, Finanz- und Ertragslage wohl zu positiv dargestellt worden sei.
Der Joyou-Vorstand wird eine außerordentliche Aktionärsversammlung einberufen und verschiebt zudem die für Freitag geplante Vorlage der Quartalsbilanz. Auch die Grohe-Mutter Lixil verschob wegen der Probleme bei Joyou die Veröffentlichung ihrer Quartalszahlen.
Pleiten, Pech und Pannen
Joyou reiht sich ein in eine lange Listen von Pleiten, Pannen und Skandalen bei chinesischen Firmen, die an der Frankfurter Börse erstnotiert sind. So flüchtete der Chef von Ultrasonic mitsamt der Firmenkasse. Auch der Youbisheng-Chef verschwand spurlos, die Firma ging pleite. Die meisten ausschließlich in Deutschland notierten China-Aktien erwiesen sich als Geldvernichter, die Geschäftsmodelle als Luftnummern.
nb/lg
MFG
Chali
IsoRay's Cesium-131 Lung Cancer Treatment Reports 96% Success in Local Control and 100% Survival at 5 Years in High Risk Patients in Newly Published Report
Cesium-131's Outstanding Lung Cancer Results Take on Other Treatment Forms Including Stereotactic Radiation
Marketwired IsoRay, Inc.
May 20, 2015 8:15 AM
Related Quotes
ISR2.00+8.70%
IsoRay, Inc.
Watchlist
2.00+0.16(+8.70%)
AMEX10:45 AM EDT
ISORAY, INC. Financials EDGAR Online Financials 3 days ago
IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price TheStreet q 4 days ago
More
RICHLAND, WA--(Marketwired - May 20, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer.
IsoRay CEO Dwight Babcock commented, "We are extremely excited to have our Cesium-131 isotope seeds and mesh used in the treatment of non-small cell lung cancers with such outstanding patient outcomes. Notable physicians, including the authors of this study, are seeking better solutions and outcomes for their patients. We are continuing to develop our product offerings internally with support from these industry leaders. With every success that has been reported, the medical community is rapidly becoming aware of the innovative alternative our Cesium-131 products offer to cancer patients."
Dr. Bhupesh Parashar MD, of Weill Cornel Medical College, is lead author of the publication titled: 'Analysis of Stereotactic Radiation vs. Wedge Resection vs Wedge Resection Plus Cesium-131 Brachytherapy in Early-stage Lung Cancer'. The study noted that the survival rate at 5 years was exceptional for the Cesium-131 group, which included many high risk patients, and Cesium-131 added no noticeable side effects. Treatment with Cesium-131 was performed at the time of the surgery as a single treatment, in contrast to another treatment option, external radiation, which requires numerous hospital visits. To review the report as published online as of May 19, 2015, please follow the link provided here: http://www.sciencedirect.com/science/article/pii/S1538472115004559
Intraday von 3,03 auf 3,16, der Widerstand im Weekly fast weg.
MFG
Chali
Ticker und Name beginnen mit S. Kleines Biotechquiz, wer hat gestern diese Meldung auch gelesen?
Da muss ich den Quizgewinn alleine einstreichen. 2000 Dollar in 18 Minuten ist ok für den Tagessatz.
Kauf 10000 Stücke zu 1,07, verkauft 10000 zu 1,27.
2000 mal 17 Cent gleich 340 Dollar für den Tagessatz.
Galena Biopharma
4 hours ago
GlobeNewswire
GALE-301 demonstrates promising preliminary efficacy data with a projected 78% reduction in relative risk of recurrence in the 1000 mcg dose cohort
Leica Biosystem's Bond Oracle HER2 Immunohistochemistry (IHC) System distinguishes HER2 1+ and 2+ expressions and supports its use as a companion diagnostic for NeuVax(TM) (nelipepimut-S)
PORTLAND, Ore., May 27, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced two abstract publications at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.
"The two abstracts published by ASCO provide meaningful advancements for both of our cancer immunotherapy programs, NeuVax and GALE-301," said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. "The use of Leica's Bond Oracle HER2 IHC system ensures we have enrolled the specified HER2 1+/2+ patients for our Phase 3 NeuVax(TM) PRESENT trial and moves us further down the path of providing targeted, personalized medicine for these women. Meanwhile, the published preliminary data from our GALE-301 program is quite promising as it shows significant reduction of recurrences with our vaccine. We expect to present more mature data at a scientific conference this Fall, and we are currently evaluating the next steps to potentially advance GALE-301 into a randomized late-stage trial to prevent recurrence in ovarian and endometrial cancers."
GALE-301
GALE-301 (E39) is a cancer immunotherapy targeting folate binding protein receptor-alpha to prevent ovarian and endometrial cancer recurrence in the adjuvant setting. In abstract #e14031, entitled, "Preliminary Results of the Phase I/IIa Dose Finding Trial of a Folate Binding Protein Vaccine (E39+GM-CSF) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence," data show that GALE-301 is well tolerated and elicits a strong and dose-dependent in vivo immune response. The trial is designed as a safety and dose optimization trial and is not powered for a disease free survival efficacy endpoint. However, early efficacy results from the trial are promising in the 1000 mcg dose cohort. Of the 51 patients enrolled in the trial, 29 were in the vaccinated group (15 patients at 1000 mcg vs. 14 patients at <1000 mcg) and 22 were in the control group. With 9.8 months median follow-up, the 1000 mcg dose group had only one clinical recurrence vs 11 in the vaccine group (6.7% vs. 50% CG, p = 0.01). Combining all dose groups, the complete response (CR) rate was 38% in the vaccine group vs. 50% in the control group (p = 0.41). Currently, the estimate for disease free survival at two years is 85.7% (1000 mcg dose group) vs. 19.2% for the control group (p = 0.09), for a 78% reduction in relative risk of recurrence. The full abstract can be found here.
NeuVax(TM) (nelipepimut-S) Companion Diagnostic
As part of the Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) trial, Galena implemented central laboratory testing for all potential patients to confirm validated and robust entry criteria, and to ensure the enrollment of the targeted patient population. To improve accuracy and specificity for the HER2 1+ and 2+ status testing, and develop a companion diagnostic for NeuVax, the Leica Bond Oracle(TM) HER2 Immunohistochemistry (IHC) system has been incorporated as central HER2 screening for the PRESENT study.
In abstract #e11609, entitled, "Analytical Validation of BOND Oracle HER2 IHC System for Identifying Low to Intermediate HER2 Expressing Breast Cancer in NeuVax PRESENT Phase 3 Clinical Trial," data demonstrate a direct correlation between cell line receptor load, quantitative measure of HER2 protein, and IHC score. The ability to discriminate HER2 protein expression at the low and intermediate levels in breast cancer tumors will identify patients for new treatments in development such as NeuVax. Specifically, the validation of the Bond Oracle HER2 IHC System to distinguish lower levels of HER2+ expressions supports its use as a companion diagnostic. The full abstract can be found here.
About GALE-301 (Folate Binding Protein)
GALE-301 (Folate Binding Protein (FBP)) is a cancer immunotherapy targeting the prevention of cancer recurrence in the adjuvant setting. GALE-301 targets folate binding protein receptor-alpha, a well-validated therapeutic target, is highly over-expressed in ovarian, endometrial and breast cancers. FBP is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes (CTLs) to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of the FBP peptide(s) combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF). Galena has completed enrollment in a Phase 2a trial with GALE-301 in two gynecological cancers: ovarian cancer and endometrial adenocarcinomas (clinicaltrials.gov identifier: NCT01580696).
Related Quotes
Diesen Kauf behalte ich, verkaufe nicht heute.
Und sonst sage ich mal Tschüss für heute, Tagesergebnis 2350 Dollar vor Steuern durch die SPHS und ISR Trades.